Topoisomerase II Isoform Divergence and Quiescent Cardiomyocyte Susceptibility
Anthracycline-induced cardiomyopathy has historically been ascribed to off-target semiquinone redox cycling and iron-catalyzed reactive oxygen species generation [1][2]. Experimental advances have revised this framework, revealing that doxorubicin toxicity is primarily governed by topoisomerase II isoform-specific interactions [1][3]. Human cells express two distinct type II topoisomerase isozymes: TOP2A (170 kDa) and TOP2B (180 kDa) [1]. TOP2A expression fluctuates through the cell cycle, peaking in the S and G2/M phases to resolve catenated DNA duplexes during chromosome segregation [1][2]. Consequently, proliferating malignant cells display elevated TOP2A levels, rendering them sensitive to doxorubicin antineoplastic cytotoxicity [2][3].
Adult mammalian ventricular cardiomyocytes are terminally differentiated, post-mitotic cells that lack TOP2A expression, relying exclusively on TOP2B for homeostatic chromatin remodeling and transcriptional regulation [1][4]. During cardiomyocyte differentiation and ontogenic maturation, a phenotypic switch occurs wherein TOP2A is downregulated below detection limits while TOP2B expression remains stable [1][5]. Doxorubicin exhibits comparable equilibrium binding and poisoning potency across both isoforms, with an IC50 of 0.4 μM to 1.5 μM for enzyme-mediated cleavage complex formation [1][5]. Because target engagement is equipotent, the absolute tissue distribution of the respective topoisomerase isozymes dictates therapeutic efficacy versus cardiotoxic liability [2][4].
As summarized in Table 1, the differential biophysical interactions of doxorubicin across topoisomerase isoforms and cardioprotective catalytic modifiers define the selective vulnerability of cardiac tissue [1][3][5]. Conditional deletion of Top2b in murine cardiomyocytes protects cardiac tissue from doxorubicin-induced myofibrillar loss, mitochondrial vacuolization, and left ventricular ejection fraction reduction, directly identifying TOP2B as the required transducer of cardiotoxicity [2][3]. In H9C2 rat cardiomyocytes and maturing human cardiomyocytes, selective target modulation highlights the distinct functional roles of these two enzymes [1][5].
Ternary Cleavage Complex Stabilization and DNA Double-Strand Break Signaling
Type II topoisomerases alter DNA topology by creating a transient 4-base-pair staggered double-strand break (DSB), passing an intact duplex through the gate, and religating the cleaved phosphodiester backbone via catalytic tyrosine residues [1][4]. Doxorubicin functions as a topoisomerase poison rather than an active-site catalytic blocker [4][5]. The aglycone anthracycline core intercalates between base pairs adjacent to the scissile phosphate bonds, while the daunosamine sugar moiety occupies the minor groove [1][4]. This structural trapping stabilizes the covalent phosphotyrosyl topoisomerase-DNA intermediate, preventing religation and generating persistent ternary cleavage complexes [3][4].
In post-mitotic cardiomyocytes, persistent ternary complexes halt transcription elongation [1][4]. Collision of the RNA polymerase II transcription machinery with immobilized TOP2B complexes triggers targeted proteasomal degradation of the enzyme, converting masked covalent adducts into naked, blunt-ended DNA double-strand breaks [4][6]. The emergence of unligated DSBs triggers rapid recruitment of the sensor complex MRE11-RAD50-NBS1, inducing autophosphorylation of ataxia telangiectasia mutated (ATM) at Ser1981 and subsequent phosphorylation of histone variant H2AX at Ser139 (γ-H2AX) within 2 hours of exposure [6].
In the human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) model, doxorubicin exposure at clinically representative concentrations (0.2 μM to 0.5 μM) induces extensive γ-H2AX and 53BP1 nuclear foci [5][6]. Because post-mitotic cardiomyocytes lack homologous recombination machinery due to absence of sister chromatids, cells rely exclusively on classical non-homologous end joining (c-NHEJ) [4][6]. Excessive Top2-mediated lesion density saturates DNA-PKcs and XRCC4-LIG4 complexes, leaving DSBs unrepaired [6]. Persistent ATM kinase signaling phosphorylates p53 at Ser15, stabilizing p53 and promoting transcriptional activation of pro-apoptotic genes including BAX, PUMA, and NOXA [4][6].
Transcriptional Arrest of Metabolic Regulators and Mitochondrial Bioenergetic Collapse
Beyond genomic instability, TOP2B trapping at specific regulatory loci suppresses the expression of cardiac metabolic master regulators [1][4]. TOP2B is localized to gene promoters and actively participates in chromatin relaxation required for rapid transcriptional initiation [1]. In quiescent cardiomyocytes, TOP2B is bound to promoter regions of PPARGC1A (encoding PGC-1α) and PPARGC1B (encoding PGC-1β) [3][4]. Formation of the doxorubicin-TOP2B-DNA cleavage complex across these promoter domains prevents open complex formation, precipitating an acute decline in PGC-1α and PGC-1β transcript levels within 6 hours of anthracycline perfusion [3][4].
Depletion of the PGC-1 transcriptional coactivator cascade downregulates downstream metabolic factors, including nuclear respiratory factor 1 (NRF-1) and mitochondrial transcription factor A (TFAM) [1][4]. TFAM reduction impairs transcription of mitochondrial DNA (mtDNA)-encoded subunits of the electron transport chain, such as MT-CO1, MT-ND1, and MT-ATP6 [1][4]. Western blot and spectrophotometric assays demonstrate significant decreases in the structural expression and enzymatic activity of Complex I, Complex III, and Complex IV [1][4].
In treated C57BL/6J ventricular myocardium, bioenergetic analyses display reductions in baseline oxygen consumption rate (OCR) and reserve respiratory capacity [1][4]. Mitochondrial transmembrane potential (ΔΨm) collapses, resulting in opened mitochondrial permeability transition pores (mPTP) and matrix swelling [1][4]. Defective electron transfer through uncoupled Complex I and Complex III accelerates univalent electron transfer to molecular oxygen, generating elevated levels of superoxide anions (O₂^{\bullet-}) and hydrogen peroxide (H₂O₂) [1][4]. This high-amplitude secondary reactive oxygen species burst oxidizes cardiolipin, promotes release of cytochrome c into the cytoplasm, and activates caspase-9 and caspase-3, sealing the apoptotic commitment of the cardiomyocyte [1][4].
Cardiomyocyte Genomic Stability Assays and TOP2B Depletion Phenotypes
Definitive attribution of anthracycline toxicity to TOP2B was established using precise genetic ablation strategies [2][3]. In the conditional Myh6-Cre;Top2b^fl/fl murine model, cardiomyocyte-specific deletion of Top2b completely protects adult mice from doxorubicin-induced cardiac injury [2][3]. Following cumulative doxorubicin administration (20 mg/kg), wild-type animals exhibit marked left ventricular fractional shortening declines, severe troponin release, elevated transcript levels of ANP/BNP, and massive mortality [2][3]. Conversely, Top2b-deficient animals show preserved systolic ejection, negligible γ-H2AX focus formation, maintained mitochondrial cristae morphology, and normal life expectancy, despite receiving identical systemic anthracycline exposures [2][3].
Comparative investigations in cultured H9C2 rat myoblasts and human cardiomyocytes confirm that genetic shRNA depletion or pharmacological clearance of TOP2B mitigates doxorubicin-induced DNA double-strand breaks [5][6]. Neutral single-cell gel electrophoresis (Comet assay) reveals that doxorubicin treatment of wild-type myocytes generates elevated olive tail moments indicative of extensive DSBs [5][6]. In contrast, cells depleted of TOP2B or cells expressing mutant forms resistant to cleavage complex formation fail to yield significant DNA fragmentation upon drug exposure [5][6].
In Sprague-Dawley rat primary ventricular cardiomyocytes, analysis of adrenergic and homeostatic signaling demonstrates that persistent TOP2B poisoning induces severe downregulation of miR-30 family microRNAs [7]. miR-30 loss upregulates connective tissue growth factor and stabilizes β1-adrenergic receptor signaling cascades towards maladaptive pro-apoptotic pathways, aggravating structural cardiac decompensation [7]. Quantitative automated high-content imaging quantifying the colocalization of cardiac troponin T (cTnT) with cleaved caspase-3 and γ-H2AX provides a robust phenotypic screening platform to distinguish direct cardiotoxic cleavage liabilities from therapeutic cytotoxic endpoints [6][7].
Translational Cardioprotection Strategies and Catalytic Decoupling Paradigms
Elucidation of the TOP2B-dependent cardiotoxic mechanism resolved longstanding ambiguities regarding the cardioprotective profile of dexrazoxane (ICRF-187) [1][3]. For decades, dexrazoxane was assumed to function through its bis-dioxopiperazine hydrolysis product (ADR-925), which chelates intracellular free iron (Fe²⁺/Fe³⁺) to suppress Fenton reactions [1][6]. Iron chelators such as deferoxamine and antioxidant scavengers such as N-acetylcysteine consistently fail to provide clinically meaningful cardioprotection in randomized human oncology trials, arguing against iron chelation as the dominant driver [1][6].
Dexrazoxane functions as a non-cleavable ATP-competitive catalytic topoisomerase II inhibitor [3][5]. Structural studies reveal that dexrazoxane binds to the N-terminal ATPase domains of both TOP2A and TOP2B, locking the dimeric enzyme into a closed-clamp conformation around intact DNA before phosphodiester bond cleavage can occur [3][5]. Pre-incubation of hiPSC-CM cultures or H9C2 rat cardiomyocytes with dexrazoxane (50 μM to 100 μM) competitively blocks doxorubicin access to the scissile DNA interface [5][6]. Furthermore, sustained closed-clamp engagement triggers rapid SUMOylation and subsequent ubiquitination of TOP2B, inducing proteasomal degradation and clearing the cellular target before anthracycline challenge [3][5].
Because dexrazoxane also inhibits TOP2A, therapeutic timing and tissue exposure must be carefully controlled to prevent interference with doxorubicin-induced tumor cell killing [1][3]. Ongoing discovery initiatives focus on developing isoform-selective TOP2B small-molecule degraders, selective catalytic inhibitors that do not engage TOP2A, and anthracycline analogues structurally modified to prevent intercalation specifically within the cardiac TOP2B cleavable complex [1][3]. Decoupling antineoplastic TOP2A cytotoxicity from quiescent cardiac TOP2B cleavage complex stabilization represents the primary design criterion for modern anthracycline chemotherapy [1][2].